Combining TACE with Atezolizumab and Bevacizumab for Unresectable Liver Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 clinical trial investigates the effectiveness of combining transarterial chemobolization (TACE) with hepatic artery infusion chemotherapy and the immunotherapy drugs atezolizumab and bevacizumab in patients with unresectable hepatocellular carcinoma (HCC). The study aims to determine whether this combination improves the objective response rate compared to existing treatments. Eligible participants will be closely monitored for their response to the treatment regimen, which includes both chemotherapy and immunotherapy components.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (a) patients were diagnozied with unresectable advanced-stage HCC,
* (b) Child-Pugh A or B liver function;
* (d) Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
* (e) adequate hematologic blood counts (white blood cell count \>3ⅹ109/L, absolute neutrophil count \>1.5ⅹ109/L, platelet count \>10ⅹ109/L, hemoglobin concentration \>85 g/L);

Exclusion Criteria:

* (a) severe underlying cardiac, pulmonary, or renal diseases;
* (b) history of a second primary malignant tumor;
* (c) contraindication to either atezolizumab and bevacizumab.

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Carbon ion radiotherapy plus atezolizumab and bevacizumab for advanced hepatocellular carcinoma

  This trial will try adding carbon ion radiotherapy to standard atezolizumab‑bevacizumab treatment for adults with advanced hepatocellular carcinoma to see if it controls tumors better and improves survival.

  Recruiting Phase 2 Yonsei University · Seoul · NCT07246668

• Combining atezolizumab and bevacizumab with Y-90 radioembolization to help people with liver cancer get to transplant

  This trial tests whether adding immunotherapy (atezolizumab plus bevacizumab) to Y-90 radioembolization can help people with hepatocellular carcinoma bridge to or be downstaged for liver transplant.

  Recruiting Phase 4 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07059494

• Preventive endoscopic banding for high-risk esophageal varices in people with hepatocellular carcinoma starting atezolizumab plus bevacizumab

  This study will test whether doing preventive endoscopic banding of high-risk esophageal varices can reduce bleeding in people with hepatocellular carcinoma who are starting atezolizumab plus bevacizumab.

  Recruiting Phase 2 Asan Medical Center · Seoul, Song-pa · NCT06819566

• Combination therapy for hepatocellular carcinoma using atezolizumab, bevacizumab, and memantine

  This study is testing a new combination of three medications to see if it can help people with advanced liver cancer feel better and improve their quality of life.

  Recruiting at 2 sites Phase 2 Inova Health Care Services · Fairfax, Virginia and 1 other locations · NCT06789757

• Combining Atezolizumab and Bevacizumab with Photon Radiotherapy for Liver Cancer

  This study is testing if combining two cancer drugs, atezolizumab and bevacizumab, with radiation therapy can help people with liver cancer that can't be surgically removed live longer and feel better.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan City, Taiwan · NCT06339424

• Valemetostat with atezolizumab and bevacizumab for advanced hepatocellular carcinoma

  This will test whether adding the oral drug valemetostat to atezolizumab and bevacizumab helps people with advanced hepatocellular carcinoma who have not received prior systemic therapy.

  Recruiting Phase 1/2 University of Alabama at Birmingham · Birmingham, Alabama · NCT06294548

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.